XML 43 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Description of Business and Significant Accounting Policies (Details) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified
1 Months Ended 3 Months Ended 134 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended
Mar. 31, 2012
Mar. 31, 2010
Mar. 31, 2012
Mar. 31, 2013
Dec. 31, 2012
Oct. 28, 2010
GSK
Original Collaboration Agreement
Oct. 31, 2010
GSK
Original Collaboration Agreement
Jul. 17, 2012
GSK
Expanded Collaboration Agreement
Jul. 31, 2012
GSK
Expanded Collaboration Agreement
Mar. 31, 2013
GSK
Expanded Collaboration Agreement
Jul. 26, 2012
GSK
SPA
Jul. 17, 2012
GSK
SPA
Jul. 31, 2012
GSK
SPA
Mar. 31, 2013
GSK
SPA
Corporate Information, Status of Operations and Management Plans                            
Percentage of development costs funded by the entity               40.00%            
Percentage of development costs funded by the counterparty               60.00%            
Price per share of common stock issued as part of the license and collaboration agreement (in dollars per share) $ 5.70 $ 3.74 $ 5.70     $ 4.56 $ 4.56         $ 6.30 $ 6.30  
Total purchase price (in dollars)                     $ 18,600,000 $ 18,600,000    
Ownership position in the company (as a percent)                   19.80%       19.80%
Accumulated deficit       (336,347,000) (318,889,000)                  
Common stock issued (in shares) 11.50 4.95             2.90          
Warrants issued (in shares)   1.9                        
Proceeds from the issuance of common stock and warrants (in dollars) $ 62,000,000 $ 17,100,000 $ 62,063,000 $ 193,441,000   $ 31,000,000 $ 31,000,000   $ 18,600,000          
Stock issued from collaboration agreement (in shares)   4.90       6.90 6.87         2.90 2.90